Copyright © 2000 by the European Society of Cardiology.
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study
a The Duke Clinical Research Institute, Durham, North Carolina, U.S.A.
b Sahlgrenska Hospital, Göteborg, Sweden
c The Cleveland Clinic Foundation, Cleveland, Ohio, U.S.A.
d Green Lane Hospital, Auckland, New Zealand
e Università deglia Studi de Pavia, Pavia, Italy
revised June 6, 2000; accepted June 7, 2000
Abstract
Aims We examined the characteristics, outcomes, and effects of hirudin vs heparin treatment of diabetic patients across the spectrum of acute coronary syndromes.
Methods and Results We studied the 12142 patients enrolled in the randomized GUSTO-IIb study. Diabetic patients (n=2175) were older, more often female, more often had prior cardiovascular disease, hypertension, and hyperlipidaemia, and less often were current smokers. Diabetic patients had a higher overall incidence of death or (re)infarction at 30 days (13·1% vs 8·5%, P=0·0001), whether they presented with ST-segment elevation (13·9% vs 9·9%, P=0·0017) or not (12·8% vs 7·8%,P =0·0001), and at 6 months (18·8% vs 11·4%, P=0·0001). Among diabetic patients, hirudin was associated with a tendency toward a lower risk of death or (re)infarction at 30 days (12·2% vs 13·9% with heparin) and 6 months (17·8% vs 20·2%). Diabetic patients had more major bleeding, stroke, heart failure, shock, atrioventricular block, and atrial arrhythmias, but no increased risk for ocular bleeding.
Conclusions Diabetic patients with acute coronary syndromes had worse 30-day and 6-month outcomes, particularly those without ST-segment elevation. The statistically non-significant trend toward improved outcomes with hirudin was similar among patients with and without diabetes, with a greater point estimate for the absolute difference in patients with diabetes.
Key Words: Unstable angina, myocardial infarction, diabetes mellitus, hirudin, heparin
f1 Correspondence: Darren K. McGuire, MD, Duke Clinical Research Institute, 7481 North Pavilion, P.O. Box 17969, Durham, NC 27715, U.S.A.
References
- Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
[Abstract/Free Full Text] - Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med. 1996;124:123–126
[Abstract/Free Full Text] - Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 1997;126:296–306
[Abstract/Free Full Text] - Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabetes Med. 1993;10:449–454[Web of Science][Medline]
- Granger CB, Califf RM, Young S. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol. 1993;21:920–925[Abstract]
- Mak KH, Moliterno DJ, Granger CB. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol. 1997;30:171–179[Abstract]
- Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1995;22:1788–1794
- Barbash GI, White HD, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol. 1993;22:707–713[Abstract]
- N Engl J Med. 1996;335:775–782
[Abstract/Free Full Text] - Circulation. 1994;90:1631–1637
[Abstract/Free Full Text] - N Engl J Med. 1993;329:673–682
[Abstract/Free Full Text] - McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J. 1999;138:S366–375[CrossRef][Web of Science][Medline]
- Mahaffey KW, Granger CB, Toth CA. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol. 1997;30:1606–1610[Abstract]
- Lancet. 1994;343:311–322[CrossRef][Web of Science][Medline]
- Malmberg K, Herlitz J, Hjalmarson A, Rydén L. Effects of metoprolol on mortality and late infarction in patients with diabetes with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J. 1989;10:423–428
[Abstract/Free Full Text] - Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285–290[Abstract]
- Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43–50
[Abstract/Free Full Text] - Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care. 1997;20:614–620[Abstract]
- Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
[Abstract/Free Full Text] - N Engl J Med. 1998;339:1349–1357
[Abstract/Free Full Text] - Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326–1331
[Abstract/Free Full Text] - Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol. 1998;82:9R–14R[Web of Science][Medline]
- Tuomilehto J, Rastenyte D, Birkenhager WH. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677–684
[Abstract/Free Full Text] - Sowers JR. Comorbidity of hypertension and diabetes: the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). Am J Cardiol. 1998;82:15R–19R[Web of Science][Medline]
- Chaitman BR, Rosen AD, Williams DO. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. Circulation. 1997;96:2162–2170
[Abstract/Free Full Text] - Circulation. 1997;96:1761–1769
[Abstract/Free Full Text] - Detre KM, Guo P, Holubkov R. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1999;99:633–640
[Abstract/Free Full Text] - Barsness GW, Peterson ED, Ohman EM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 1997;96:2551–2556
[Abstract/Free Full Text] - Weintraub WS, Stein B, Kosinski A. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol. 1998;31:10–19
[Abstract/Free Full Text] - Mazzanti L, Mutus B. Diabetes-induced alterations in platelet metabolism. Clin Biochem. 1997;30:509–515[CrossRef][Web of Science][Medline]
- Davi G, Catalano I, Averna M. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769–1774[Abstract]
- Banga JD, Sixma JJ. Diabetes mellitus, vascular disease and thrombosis. Clin Haematol. 1986;15:465–492[Web of Science][Medline]
- N Engl J Med. 1998;338:1488–1497
[Abstract/Free Full Text] - N Engl J Med. 1998;338:1498–1505
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Eur. Heart J., December 1, 2008; 29(23): 2909 - 2945. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mudespacher, D. Radovanovic, E. Camenzind, M. Essig, O. Bertel, P. Erne, F. R. Eberli, and F. Gutzwiller Admission glycaemia and outcome in patients with acute coronary syndrome Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 346 - 352. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Kapur and R. De Palma Mortality after myocardial infarction in patients with diabetes mellitus Heart, December 1, 2007; 93(12): 1504 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Norhammar, J. Lindback, L. Ryden, L. Wallentin, U. Stenestrand, and on behalf of the Register of Information and Knowl Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission Heart, December 1, 2007; 93(12): 1577 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Ray, C. P. Cannon, D. A. Morrow, A. J. Kirtane, J. Buros, N. Rifai, C. H. McCabe, C. M. Gibson, and E. Braunwald Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18 Eur. Heart J., April 2, 2007; (2007) ehm010v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]
|
|
|
|
|
|
C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71. [Abstract] [PDF]
|
|
|
|
|
|
D. V. Anand, E. Lim, A. Lahiri, and J. J. Bax The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects Eur. Heart J., April 2, 2006; 27(8): 905 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. X. Brogan Jr, E. D. Peterson, J. Mulgund, D. L. Bhatt, E. M. Ohman, W. B. Gibler, C. V. Pollack Jr, M. E. Farkouh, and M. T. Roe Treatment Disparities in the Care of Patients With and Without Diabetes Presenting With Non-ST-Segment Elevation Acute Coronary Syndromes Diabetes Care, January 1, 2006; 29(1): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heeschen Biomarkers in acute coronary syndromes and their role in diabetic patients Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 122 - 127. [Abstract] [PDF]
|
|
|
|
|
|
M. Bartnik, K. Malmberg, and L. Ryden Management of patients with type 2 diabetes after acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 144 - 154. [Abstract] [PDF]
|
|
|
|
|
|
G. G. Schwartz, A. G. Olsson, M. Szarek, and W. J. Sasiela Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial Diabetes Care, October 1, 2005; 28(10): 2508 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Svensson, D. K. McGuire, P. Abrahamsson, and M. Dellborg Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events Eur. Heart J., July 1, 2005; 26(13): 1255 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koga, S. Sugiyama, K. Kugiyama, K. Watanabe, H. Fukushima, T. Tanaka, T. Sakamoto, M. Yoshimura, H. Jinnouchi, and H. Ogawa Elevated Levels of VE-Cadherin-Positive Endothelial Microparticles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1622 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. de Araujo Goncalves, J. Ferreira, C. Aguiar, and R. Seabra-Gomes TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS Eur. Heart J., May 1, 2005; 26(9): 865 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T S Fergus, R Fazel, J Fang, S Chetcuti, D E Smith, E Kline-Rogers, K Munir, K A Eagle, and D Mukherjee Presentation, management, and outcomes of diabetic patients compared to non-diabetic patients admitted for acute coronary syndromes Heart, September 1, 2004; 90(9): 1051 - 1052. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Franklin, R. J. Goldberg, F. Spencer, W. Klein, A. Budaj, D. Brieger, M. Marre, P. G. Steg, N. Gowda, J. M. Gore, et al. Implications of Diabetes in Patients With Acute Coronary Syndromes: The Global Registry of Acute Coronary Events Arch Intern Med, July 12, 2004; 164(13): 1457 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raggi, L. J. Shaw, D. S. Berman, and T. Q. Callister Prognostic value of coronary artery calcium screening in subjects with and without diabetes J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1663 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Gurm, A. M. Lincoff, D. Lee, W. H. W. Tang, G. Jia, J. E. Booth, R. M. Califf, E. M. Ohman, F. Van de Werf, P. W. Armstrong, et al. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: Lessons from the GUSTO V trial J. Am. Coll. Cardiol., February 18, 2004; 43(4): 542 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Norhammar, K. Malmberg, E. Diderholm, B. Lagerqvist, B. Lindahl, L. Ryden, and L. Wallentin Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization J. Am. Coll. Cardiol., February 18, 2004; 43(4): 585 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. L Williams, B. Noronha, and A. G Zaman Review: The management of acute myocardial infarction in patients with diabetes mellitus The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 319 - 324. [Abstract] [PDF]
|
|
|
|
|
|
C. Borghi, S. Bacchelli, D. D. Esposti, and E. Ambrosioni Effects of the Early ACE Inhibition in Diabetic Nonthrombolyzed Patients With Anterior Acute Myocardial Infarction Diabetes Care, June 1, 2003; 26(6): 1862 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Tedesco, R. S. Wright, B. A. Williams, S. L. Kopecky, D. L. Dvorak, G. S. Reeder, W. L. Miller, and Mayo Coronary Care Unit Group Effect of Diabetes on the Mortality Risk of Cardiogenic Shock in a Community-Based Population Mayo Clin. Proc., May 1, 2003; 78(5): 561 - 566. [Abstract] [PDF]
|
|
|
|
|
|
M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF]
|
|
|
|
|
|
V. S. Moiseyev, P. Poder, N. Andrejevs, M. Y. Ruda, A. P. Golikov, L. B. Lazebnik, Z. D. Kobalava, L. A. Lehtonen, T. Laine, M. S. Nieminen, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur. Heart J., September 2, 2002; 23(18): 1422 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White and C. K. Wong Risk stratification and treatment benefits in patients with non-ST-elevation acute coronary syndromes Eur. Heart J., February 1, 2002; 23(3): 187 - 191. [Full Text] [PDF]
|
|
|
|
|
|
E. Erdmann Cardiovascular events in patients with type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1_suppl): S4 - S8. [Abstract] [PDF]
|
|
|
|
|
|
D. L. Dries, N. K. Sweitzer, M. H. Drazner, L. W. Stevenson, and B. J. Gersh Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction J. Am. Coll. Cardiol., August 1, 2001; 38(2): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Gustafsson and P. Hildebrandt Blood glucose in the CCU: time to measure Eur. Heart J., July 1, 2001; 22(13): 1061 - 1062. [PDF]
|
|
|
|
|
|
P. Hildebrandt Diabetic patients and acute coronary syndromes Eur. Heart J., June 1, 2001; 22(11): 887 - 888. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||